Horyzons: Implementation and Integration in Clinical Practice

Summary

The primary aim of this trial is evaluating the barriers and enablers of implementing a digital intervention with both therapeutic content and social networking, Horyzons, as part of clinical care in first episode psychosis (FEP) clinics in North Carolina. Providers (clinicians and peers support specialists) will be recruited from FEP clinics to assess Horyzons implementation and integration within clinical care at three time points (baseline, 6 months, and 12 months). Further, individuals experiencing FEP between the ages of 16 and 35 receiving services from the FEP clinics will be recruited to engage with the platform over the course of 12 months. Due to the nature of the digital intervention being implemented across the state of North Carolina, all research visits will be conducted remotely via videoconferencing.

Conditions

• Schizophrenia
• Schizophreniform Disorders
• Schizoaffective Disorder
• Unspecified or Other Psychotic Disorders

Interventions

DEVICE

Horyzons USA

Client participants will be onboarded to the digital platform, including the different spaces and how to use the site. The site includes therapeutic content that is tailored to each individual and their current needs and experiences, including social anxiety, generalized anxiety, mood, and social functioning, and distress intolerance. Further, the platform includes a moderated social media function, where individuals and peer support specialists can post text, images, videos, and comments to connect and share their experiences. The site is monitored by graduated students and trained clinicians.

Sponsors & Collaborators

• North Carolina Department of Health and Human Services

  collaborator OTHER_GOV

• University of North Carolina, Chapel Hill

  lead OTHER

Principal Investigators

• David Penn, PhD · University of North Carolina, Chapel Hill

• Diana Perkins, MD, MPH · Univeristy of North Carolina, School of Medicine

• Felice Reddy, PhD · University of North Carolina, Chapel Hill

Study Design

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

16 Years

Max Age

35 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2024-01-08

Primary Completion

2024-10-31

Completion

2024-10-31

FDA Device

Yes

Countries

• United States

Study Locations